Similar to AD, patients with PD could benefit from a triad of biologics that include: (a) biologic TNFIs that suppress the neuroinflammation that occurs in brain in PD (McCoy et al., 2006); (b) therapeutic antibodies that block the formation of α-synuclein aggregates in PD (Schofield et al., 2019); and (c) neurotrophins that induce repair of dystrophic neurites in PD. The gene discussed is BDNF; the disease is Alzheimer disease.